Expanding spectrum of opportunistic infections associated with dimethyl fumarate

Abstract

Background:

Only progressive multifocal leukoencephalopathy (PML) is currently described in the dimethyl fumarate (DMF) prescribing information.

Objectives:

To describe opportunistic infections (OIs), other than PML, reported in association with DMF.

Methods:

The FDA Adverse Event Reporting System (FAERS) and medical literature were searched.

Results:

We retrieved 34 cases of serious OIs with a causal association with DMF, including 11 central nervous system (CNS) infections and 23 extra-CNS infections. Six OIs occurred with normal circulating absolute lymphocyte counts. The median latency from DMF initiation was 13 months and was variable.

Conclusion:

DMF is associated with the development of OIs that require invasive diagnostic and/or therapeutic procedures. Patients should be monitored for OIs when treated with DMF regardless of circulating absolute lymphocyte counts.

Keywords

Multiple sclerosis dimethyl fumarate immunology

Get full access to this article

View all access options for this article.

References

Fox

Miller

Phillips

, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097.

Gold

Kappos

Arnold

, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098–1107.

Longbrake

Naismith

Parks

, et al. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Mult Scler J Exp Transl Clin. Epub ahead of print 31 July 2015. DOI: 10.1177/2055217315596994.

Warny

Helby

Nordestgaard

, et al. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med 2018; 15(11): e1002685.

Shapiro

Karras

Leech

, et al. Absolute lymphocyte count as a predictor of CD4 count. Ann Emerg Med 1998; 32(3 Pt 1): 323–328.

Biogen Inc. Tecfidera (Package Insert). Cambridge, MA: Biogen Inc, 2020.

U.S. Food & Drug Administration. Questions and Answers on FDA’s Adverse Event Reporting System (FAERS), 2018, https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ (accessed 1 July 2020).

Postmarketing reporting of adverse drug experiences—Electronic Code of Federal Regulations title 21: Food and drugs part 314, https://www.ecfr.gov/cgi-bin/text-idx?SID=eb822077c27330d63a938f32733fd508&mc=true&node=se21.5.314_180&rgn=div8 (accessed 1 July 2020).

U.S. Food & Drug Administration. Guidance for industry: Good pharmacovigilance practices and pharmacoepidemiologic assessment. Silver Spring, MD: U.S. Food & Drug Administration, 2005.

10.

Spencer

Crabtree-Hartman

Lehmann-Horn

, et al. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2015; 2: e76.

11.

Gross

Schulte-Mecklenbeck

Klinsing

, et al. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3: e183.

12.

Goldman

SA.

Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20(Suppl. C): C40–C44.